Last reviewed · How we verify
NCT04390711
Association of Carbamylated HDL and CAD in T2DM Patients
trial testing High density lipoprotein isolation, detection and in-vitro study. in Type 2 Diabetes Mellitus With Circulatory Complciation in 282 participants. Completed in 30 March 2019.
30 March 2019
Quick facts
| Lead sponsor | RenJi Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 282 |
| Start date | 1 September 2018 |
| Primary completion | 30 March 2019 |
| Estimated completion | 30 March 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- High density lipoprotein isolation, detection and in-vitro study.
Conditions studied
- Type 2 Diabetes Mellitus With Circulatory Complciation — all drugs for Type 2 Diabetes Mellitus With Circulatory Complciation →
Sponsor
RenJi Hospital
Who can join
Adults 40 to 90, any sex, with Type 2 Diabetes Mellitus With Circulatory Complciation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an observational cross-sectional study aimed at investigating the alterations of the carbamylated-HDL levels in T2DM patients, and comparing the concentration of carbamylated-HDL between the T2DM patients with CAD and without CAD to explore the association between carbamylated-HDL and risk of CAD in T2DM patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Association of carbamylated high-density lipoprotein with coronary artery disease in type 2 diabetes mellitus: carbamylated high-density lipoprotein of patients promotes monocyte adhesion.
Chen Z, Ding S, Wang YP, Chen L, et al · · 2020 · cited 16× · PMID 33272295 · DOI 10.1186/s12967-020-02623-2
Verify or expand the search:
- PubMed search for NCT04390711
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other RenJi Hospital trials
Trials by the same sponsor.
- NCT07584733 — Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper · Phase 2 · not yet recruiting
- NCT07537725 — EEG-TMS for Postoperative Delirium After Cardiac Surgery · NA · not yet recruiting
- NCT07527936 — A Study of BEN301 Injection in theTreatment of Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
- NCT07343076 — Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE · NA · not yet recruiting
- NCT07449793 — Biochemical Response and Clinical Outcomes in Patients With PBC · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04390711 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by RenJi Hospital
- Last refreshed: 18 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04390711.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing